Table 2.
HCA for the in silico selected compounds against SARS-CoV2.
| Compound | EC50a (μM) (mean ± SD)b | CC50c (μM) (mean ± SD) |
|---|---|---|
| Alectinib | n.a. | n.a. |
| Tedizolid | n.a. | n.a. |
| Ponatinib | 1.1 ± 0.2 | 8.7 ± 3.8 |
| Carbenoxolone | 66 ± 11 | >100 |
| Lurasidone | 18.0 ± 4.6 | >1000 |
| Cefoperazone | n.a. | n.a. |
| Elbasvir | 23.0 ± 3.6 | >1000 |
| Teniposide | 97.0 ± 0.7 | >100 |
| Venetoclax | 6.2 ± 0.6 | 22.0 ± 6.2 |
| Irinotecan | 85.2 ± 17.0 | >100 |
| Simeprevir | 9.3 ± 2.0 | 47.5 ± 41.0 |
| Grazoprevir | 16.0 ± 5.7 | 118 ± 6 |
| Natamycin | 24.3 ± 4.4 | 35.9 ± 13.4 |
| Suramin | 64.0 ± 6.6 | >100 |
n.a. not assessable.
a
Half maximal effective concentration.
b
Standard deviation.
c
Half maximal cytotoxic concentration.